November 2017

Contents

Editorial

• November/December 2017: Volume 18 Number 11/12

• i-Base 2017 appeal: we need your help….

Supplements

• PrEP for women and PrEP in the UK: new leaflets

• Guide to changing treatment: what to do if your viral load rebounds

Conference reports

• 16th European AIDS Conference (EACS 2017)

• Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

• D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

• Dolutegravir-based dual therapy as switch option in multiple studies

• Switch study shows F/TAF non-inferior to continuing abacavir/3TC

• Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

• No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

• Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS

• Dolutegravir use in pregnancy: results from small Belgian cohort

• No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

• Updated European guidelines launched at EACS 2017

• ABX464 nudges viral reservoir but not time to viral rebound

• 8th International Workshop on HIV & Ageing, 2–3 October 2017, New York

• Selected webcasts from 8th HIV and ageing workshop

• 8th HIV and Ageing Workshop: reports at natap.org

• 9th IAS Conference on HIV Science (IAS 2017)

• Reassuring French data using raltegravir during pregnancy

• Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

• Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Antiretrovirals

• Long-acting ART for children is a deferred priority despite achievable dosing

• Coformulated dolutegravir plus rilpivirine approved in US (Juluca)

• Darunavir-based single pill FDC approved in EU (Symtuza)

Treatment access

• MSF secures generic hepatitis C treatment at $120 per course

Guidelines

• Sexual and reproductive health: draft UK guidelines online for comment (2017)

Side effects

• Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?

Coinfections and complications

• Reducing rates of HIV-related cancer in US from 1996-2012

HIV prevention and transmission

• Updates from the PrEP IMPACT study – November 2017

Cure-related research

• Estimating the total size of the HIV reservoir

On the web

• Conference materials online

• Recent peer-review studies

PDFs

• November/December 2017: Volume 18 Number 11/12